WisdomTree BioRevolution FundWDNA
WDNA
0
Funds holding %
of 6,823 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
29% more capital invested
Capital invested by funds: $192K [Q2] → $247K (+$55.8K) [Q3]
1.9% more ownership
Funds ownership: 8.07% [Q2] → 9.97% (+1.9%) [Q3]
0% more funds holding
Funds holding: 3 [Q2] → 3 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for WDNA.
Financial journalist opinion
Positive
ETF Trends
1 month ago
Opportunities in Biotechnology Will Follow Advancements in the Science
By Christopher Gannatti, CFA Key Takeaways Recent advancements in GLP-1 drugs, such as Ozempic and Wegovy, underscore their potential to transform health care by addressing obesity, cardiovascular diseases and even neurodegenerative conditions.
Neutral
ETF Trends
1 year ago
Why We Loved Bill Gates's Annual Letter
By Christopher Gannatti, CFA, Global Head of Research We have been writing a lot about artificial intelligence (AI) and the ways in which we believe that topic will continue to evolve as the calendar changes from 2023 to 2024.
Positive
ETF Trends
1 year ago
Wager on WDNA for Biotech Rebound
It's been a lengthy of stretch of subpar performance by biotech stocks and related exchange traded funds. That's a scenario that will repeat this year.
Charts implemented using Lightweight Charts™